Drug Profile
Research programme: HDAC6 inhibitors - Celgene
Alternative Names: ACY 1083; ACY-738Latest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Dana-Farber Cancer Institute; Harvard University
- Developer Acetylon Pharmaceuticals; Celgene Corporation
- Class Small molecules
- Mechanism of Action HDAC6 protein inhibitors; Histone deacetylase inhibitors; Interleukin 10 inhibitors; Programmed cell death 1 ligand 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cardiovascular disorders; Charcot-Marie-Tooth disease; Chronic lymphocytic leukaemia; Depressive disorders; Diabetes mellitus; Haematological malignancies; Neurological disorders; Stroke
Most Recent Events
- 28 May 2020 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in USA
- 28 Feb 2020 No recent reports of development identified for preclinical development in Charcot-Marie-Tooth-disease in United Kingdom (PO)
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb